Clear Search

Showing 3 results for “LILAC”.

May 2023

Litifilimab (BIIB059), a Promising Investigational Drug for Cutaneous Lupus Erythematosus

Expert Opin Investig Drugs 2023;15:1-9 doi 10.1080/13543784.2023.2212154

Cho, et al. discuss the current challenges in the approval of CLE drugs and suggest outcome measures that could streamline the process. They also discuss the pharmacodynamics of litifilimab and the current status of clinical trials.

more…

November 2022

Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus

N Engl J Med. 2022;387(10):894–904 doi: 10.1056/NEJMoa2118025

Phase 2 study, in patients with systemic lupus erythematosus, shows that litifilimab is associated with a greater reduction from baseline in the number of swollen and tender joints than placebo, over a period of 24 weeks.

more…

September 2022

Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus

N Engl J Med. 2022;387(4):321–331 doi: 10.1056/NEJMoa2118024

Phase II study, in patients with active cutaneous lupus erythematosus, shows that litifilimab improved scores on a measure of skin disease activity, over 16 weeks, compared to placebo.

more…